Literature DB >> 22621189

CD158k/KIR3DL2 and NKp46 are frequently expressed in transformed mycosis fungoides.

Nicolas Ortonne, Sabine Le Gouvello, Reka Tabak, Anne Marie-Cardine, Julie Setiao, François Berrehar, Alexandra Nghe-Tang, Nadine Martin, Martine Bagot, Armand Bensussan.   

Abstract

Malignant Sezary cells express the natural killer (NK) receptors KIR3DL2 (CD158k) and Nkp46 and may co-express activating killer immunoglobulin-like receptors (KIR) that may participate to neoplastic T-cell activation through the JNK pathway. Little is known regarding NK receptor expression in other cutaneous T-cell lymphomas. We studied the expression of KIR and natural cytotoxicity receptor (NCR) transcripts, and KIR3DL1/2 at the protein level, in 16 skin biopsies from 10 patients with transformed mycosis fungoides (tMF). Some KIR and NCR transcripts were found in all cases, with various repertoires. Two to nine different KIR receptors were expressed in a single biopsy. Among them, KIR3DL2 was the most frequent, with the highest level of expression in quantitative analyses and correlated with in situ protein expression, while phosphorylated JNK was never detected. Among NCR, NKp46 was expressed in all investigated cases. The role of KIR3DL2 and NKp46 in tMF oncogenesis remains to be studied.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22621189     DOI: 10.1111/j.1600-0625.2012.01489.x

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  9 in total

1.  NKp46-specific expression on skin-resident CD4(+) lymphocytes in mycosis fungoides and Sézary syndrome.

Authors:  Pierre Schneider; Louis-François Plassa; Philippe Ratajczak; Christophe Leboeuf; Laurence Verneuil; Maxime Battistella; Armand Bensussan; Martine Bagot; Anne Janin
Journal:  J Invest Dermatol       Date:  2013-07-30       Impact factor: 8.551

Review 2.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

Review 3.  Proteomic Approaches to Biomarker Discovery in Cutaneous T-Cell Lymphoma.

Authors:  Alexandra Ion; Iris Maria Popa; Laura Maria Lucia Papagheorghe; Cristina Lisievici; Mihai Lupu; Vlad Voiculescu; Constantin Caruntu; Daniel Boda
Journal:  Dis Markers       Date:  2016-10-16       Impact factor: 3.434

4.  New Targeted Treatments for Cutaneous T-cell Lymphomas.

Authors:  Martine Bagot
Journal:  Indian J Dermatol       Date:  2017 Mar-Apr       Impact factor: 1.494

Review 5.  Therapeutic Antibodies to KIR3DL2 and Other Target Antigens on Cutaneous T-Cell Lymphomas.

Authors:  Christian Schmitt; Anne Marie-Cardine; Armand Bensussan
Journal:  Front Immunol       Date:  2017-08-30       Impact factor: 7.561

Review 6.  Novel and Future Therapeutic Drugs for Advanced Mycosis Fungoides and Sézary Syndrome.

Authors:  Tomonori Oka; Tomomitsu Miyagaki
Journal:  Front Med (Lausanne)       Date:  2019-05-29

Review 7.  Novel targeted therapies of T cell lymphomas.

Authors:  Katarzyna Iżykowska; Karolina Rassek; Dorota Korsak; Grzegorz K Przybylski
Journal:  J Hematol Oncol       Date:  2020-12-31       Impact factor: 17.388

8.  Single-cell transcriptomics links malignant T cells to the tumor immune landscape in cutaneous T cell lymphoma.

Authors:  Xiangjun Liu; Shanzhao Jin; Simeng Hu; Ruoyan Li; Haihao Pan; Yi Liu; Pan Lai; Deshu Xu; Jingru Sun; Ziyang Liu; Yumei Gao; Yifan Zhao; Fengjie Liu; Yu Xiao; Yingyi Li; Yujie Wen; Zhuojing Chen; Bufang Xu; Yuchieh Lin; Menglong Ran; Qianxi Li; Shuxia Yang; Hang Li; Ping Tu; Muzlifah Haniffa; Sarah A Teichmann; Fan Bai; Yang Wang
Journal:  Nat Commun       Date:  2022-03-03       Impact factor: 17.694

9.  Thymocyte selection-associated high mobility group box gene (TOX) is aberrantly over-expressed in mycosis fungoides and correlates with poor prognosis.

Authors:  Yuanshen Huang; Ivan V Litvinov; Yang Wang; Ming-Wan Su; Ping Tu; Xiaoyan Jiang; Thomas S Kupper; Jan P Dutz; Denis Sasseville; Youwen Zhou
Journal:  Oncotarget       Date:  2014-06-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.